Close
Blog & Resources Camargo Blog September 13th, 2007

MDS Bioanalytical Audits

MDS Pharma is back to profitability after shedding its bioanalytical facility in Montreal. This lab conducted analyses of 100’s of bioequivalence studies. FDA audited the lab several times, effectively shut down the lab and called into question the acceptability of the BE study conclusions that were used to approve many ANDA’s. FDA required the ANDA sponsors to audit every study conducted since 2000. Camargo was selected by some sponsors to perform these audits. In earlier studies (<~2003) we observed many failures to follow SOPs resulting in incorrect data and questionable actions, but the 2004 studies we audited showed excellent compliance.

Since inception, Camargo has conducted an audit of the bioanalytical assay results from all of our preferred bioanalytical labs, including MDS. Clients often wonder if this additional cost is worthwhile. What do you think?


Categories: Services

Get Our Expertise Working for You

To learn how you can benefit from our regulatory and strategic development expertise, view our solutions or contact us.


Camargo Pharmaceutical Services provides comprehensive drug development solutions, specializing in customized programs including the 505(b)(2) pathway.


Contact
Headquarters
9825 Kenwood Road
Suite 203
Cincinnati OH, 45242
Durham Office
800 Taylor Street
Suite 101, Mill No. 1
Durham NC, 27701
Montreal Office
507 Place d'Armes
Suite 1101
Montreal, QC H2Y 2W8, Canada
Phone 513.561.3329
Toll Free 888.451.5708
Subscribe for our Latest Insights